Introgen strikes nanotech deal with M.D. Anderson
16th Nov 2006, 20:41 GMT
Introgen Therapeutics Inc., an Austin biotech company working on novel cancer therapies, has obtained an exclusive, worldwide license to a portfolio of patents from The University of Texas M.D. Anderson Cancer Center in Houston.
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- United BioSource makes 10th buy, looks for more
- Nonprofits starting to invest in drug companies
- Accentia making changes to its business formula, market focus
- GSK terminates agreement for Genaera frog product
- Gladstone and Merck team to bring drugs to market
- Abbott expects to double vascular business sales
- Mayo to shut down drug-testing unit
- MIT, Dana-Farber win major cancer grants
- Service Bancorp chair resigns
- Joslin spins out first-ever company, Veraxa Health Inc.